Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA-CD16A CAR-T cells
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
PSMA-CD16A CAR-T cells are an investigational adoptive cellular therapy designed for the treatment of prostate cancer. This specific chimeric antigen receptor (CAR) construct features a humanized J591-derived single-chain variable fragment (scFv) targeting Prostate-Specific Membrane Antigen (PSMA), fused to the transmembrane and intracellular signaling domains of CD16A (FcγRIIIa). Notably, the architecture omits canonical co-stimulatory domains such as 4-1BB or CD28, relying instead on the distinct signaling profile of the innate immune receptor CD16A. This design is intended to maintain robust antitumor cytotoxicity while attenuating the secretion of pro-inflammatory cytokines (TNF-α, IFN-γ, IL-2), potentially reducing the risk of cytokine release syndrome (CRS). Preclinical studies in LNCaP xenograft models have demonstrated antigen-dependent cytotoxicity, significant tumor regression, and improved overall survival compared to control groups.
- Other names
- PSMA-CD16A CARPSMA-CD-16A CARPSMA-CD 16A CARPSMA-targeted CD16A-signaling CAR-T cells
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on PSMA-CD16A CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMA-CD16A CAR-T cells.